NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-17-285 from the NIH Guide for Grants and Contracts. The purpose of this FOA is encourage applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) Defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD
Funding Opportunity PA-17-284 from the NIH Guide for Grants and Contracts. The purpose of this FOA is encourage applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD
Notice NOT-HG-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-DA-17-038 from the NIH Guide for Grants and Contracts
Notice NOT-AG-17-008 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-282 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.
Funding Opportunity PA-17-283 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.
Notice NOT-RM-17-021 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-020 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-019 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-018 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-279 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.
Funding Opportunity PA-17-278 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals
Funding Opportunity RFA-DA-18-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage small businesses (SBCs) to develop next generation wearables and supporting mobile applications to identify digital biomarkers associated with reinitiating drug use and relapse, and create a model for just-in-time intervention.
Funding Opportunity RFA-HL-18-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications for implementation research in the delivery of proven effective interventions for co-occurring heart, lung, blood, and sleep (HLBS) diseases and conditions among people living with HIV/AIDS. Proven effective interventions and management guidelines exist for co-morbid HLBS diseases and disorders for people living with HIV. However, these interventions have not been fully implemented among people living with HIV/AIDS and gaps in care remain. The intent of this FOA is to stimulate the use of late-stage T4 translation research and implementation science strategies to address barriers that impede the scale-up and application of proven effective interventions in community and clinical settings for the prevention, control, and treatment of co-morbid HLBS conditions for people living with HIV.
Funding Opportunity PA-17-280 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to: (a) stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection to accelerate drug discovery/drug development in HBV/HIV co-infection; and (b) stimulate and accelerate a better understanding of the immunopathogenic interactions between HBV and HIV.
Funding Opportunity PA-17-281 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to: (a) stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection to accelerate drug discovery/drug development in HBV/HIV co-infection; and (b) stimulate and accelerate a better understanding of the immunopathogenic interactions between HBV and HIV.
Notice NOT-DK-17-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-18-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit applications proposing research that can lead to advancements in the understanding of elder mistreatment (emotional abuse, physical abuse, and sexual abuse; financial exploitation; abandonment; and neglect) and lay the foundation for the future design of mechanistically focused interventions for individuals at risk for mistreating elders, for promoting recovery and resilience in the maltreated and their families, and for preventing re-perpetration for those who have inflicted harm. Applications are solicited from multidisciplinary teams which include researchers from the fields of elder mistreatment, child abuse and neglect, intimate partner violence, and/or emergency medicine to pursue research in two priority areas: (1) the development of new and innovative tools and methods for the screening and detection of elder mistreatment; and (2) the identification of modifiable risk factors for elder mistreatment and modifiable protective factors, with potential to prevent maltreatment and/or enable individuals who have been mistreated and those who have mistreated others to overcome adversity and thrive. All applications should propose evidence-based strategies for addressing ethical challenges surrounding informed consent and study design in the research proposed, and to employ, when possible, best practices established in the fields of child abuse and neglect and/or intimate partner violence.
Funding Opportunity PA-17-286 from the NIH Guide for Grants and Contracts. The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.